Dianthus Therapeutics, Inc. (DNTH)
(Delayed Data from NSDQ)
$21.77 USD
-1.28 (-5.55%)
Updated May 23, 2024 04:00 PM ET
After-Market: $21.76 -0.01 (-0.05%) 5:42 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DNTH 21.77 -1.28(-5.55%)
Will DNTH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNTH
The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
Other News for DNTH
Intel upgraded, Texas Instruments initiated: Wall Street's top analyst calls
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 60 Degrees Pharmaceuticals, Inc. (SXTP), GoodRx Holdings (GDRX) and Dianthus Therapeutics (DNTH)
Dianthus Therapeutics’ DNTH103: A Potential Game-Changer in Autoimmune Disease Treatment
Dianthus initiated with bullish view at H.C. Wainwright, here's why
H.C. Wainwright starts Dianthus as buy, cites lead drug candidate